PF-06252616

BIOLOGICAL3 trials

Sponsors

Pfizer

Conditions

Duchenne Muscular DystrophyHealthy

Phase 1

A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects

CompletedNCT01616277

Start: 2012-06-30End: 2014-08-31Target: 86Updated: 2014-09-25

Phase 2

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

TerminatedNCT02310763

PfizerDuchenne Muscular Dystrophy

Start: 2014-11-24End: 2018-11-23Updated: 2020-12-07

An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

TerminatedNCT02907619

PfizerDuchenne Muscular Dystrophy

Start: 2016-10-13End: 2018-11-22Updated: 2020-11-23

Related Papers

Relationship Between Quantitative Magnetic Resonance Imaging Measures and Functional Changes in Patients With Duchenne Muscular Dystrophy

Muscle & Nerve2024-12-234 citations

Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy.

2022-11-0510 citations

Population <scp>PK</scp> and <scp>PD</scp> Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy

Clinical Pharmacology & Therapeutics2022-09-157 citations

Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial

PLoS ONE2022-08-2312 citations

Muscular myostatin gene expression and plasma concentrations are decreased in critically ill patients.

2022-08-034 citations

Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab

Journal of Neurology2022-04-0823 citations

Safety and Disease Monitoring Biomarkers in Duchenne Muscular Dystrophy: Results From A Phase Ii Trial

Biomarkers in Medicine2021-09-1717 citations

Quantitative Muscle Mri Biomarkers in Duchenne Muscular Dystrophy: Cross-Sectional Correlations with Age and Functional Tests

Biomarkers in Medicine2021-06-2232 citations

Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy

Neuromuscular Disorders2020-05-1963 citations